Rhenman & Partners Asset Management’s Myriad Genetics MYGN Stock Holding History

Rhenman & Partners Asset Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-60,000	Closed	-$2.12M	–	98
2015 Q1	$2.12M	Buy	60,000 +10,000	+20%	+$358K	0.36%	83
2014 Q4	$1.7M	Buy	+50,000	New	+$1.77M	0.49%	77
2014 Q3	–	Sell	-80,000	Closed	-$3.11M	–	102
2014 Q2	$3.11M	Buy	80,000 +55,432	+226%	+$2.06M	0.92%	35
2014 Q1	$840K	Sell	24,568 -56,191	-70%	-$1.74M	0.25%	84
2013 Q4	$1.69M	Buy	+80,759	New	+$2.04M	0.66%	67

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rhenman & Partners Asset Management's MYGN Position: Q2 2015 in Review

Rhenman & Partners Asset Management sold out of Myriad Genetics (MYGN) in Q2 2015, closing a stake of 60,000 shares — an estimated $2.12M sold.

Rhenman & Partners Asset Management first reported a position in MYGN in Q4 2013 and held it in 5 quarters. The position peaked at $3.11M in Q2 2014. 234 funds tracked by Wall St. Rank hold MYGN as of Q2 2015.

Rhenman & Partners Asset Management reported no remaining Myriad Genetics position as of Q2 2015 after selling out during the quarter.
Rhenman & Partners Asset Management sold 60,000 Myriad Genetics shares in Q2 2015, an estimated $2.12M.
Rhenman & Partners Asset Management first reported a position in Myriad Genetics in Q4 2013 and held it in 5 quarters.
Rhenman & Partners Asset Management's Myriad Genetics position peaked at $3.11M in Q2 2014.
234 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2015.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2015, filed 30 Jul 2015.